Outcomes of corticosteroid therapy in patients with viral community-acquired pneumonia.
Community-acquired pneumonia
Corticosteroids
Viral pneumonia
Virus
Journal
Pneumonia (Nathan Qld.)
ISSN: 2200-6133
Titre abrégé: Pneumonia (Nathan)
Pays: England
ID NLM: 101663459
Informations de publication
Date de publication:
25 Sep 2024
25 Sep 2024
Historique:
received:
19
07
2024
accepted:
03
09
2024
medline:
25
9
2024
pubmed:
25
9
2024
entrez:
24
9
2024
Statut:
epublish
Résumé
The objective of this study was to assess the therapeutic effects of corticosteroids in adult patients hospitalized with viral community-acquired pneumonia. This is a retrospective analysis of data collected prospectively from November 1996 to June 2024. All adult patients with viral community-acquired pneumonia were enrolled. The primary outcome was 30-day mortality. Secondary outcomes included all-cause in-hospital mortality, ICU admission, length of ICU and hospital stay, mechanical ventilation, and 1-year mortality. Propensity score matching (PSM) was used to obtain balance among the baseline variables in the two groups. Of the 524 patients with viral pneumonia, 30 (6%) received corticosteroids and 494 (94%) did not. Patients were primarily male (n = 299, 57%), with a median [Q1-Q3] age of 66.9 [55-81] years. The 3:1 propensity matching procedure identified 90 patients not treated with corticosteroid (CS-) as controls. After PSM, no difference in 30-day mortality was found [7% (95%CI 1 to 22%) vs. 4% (95%CI 1 to 11%), p = 0.639]. The risk of death at 30 days did not differ significantly in unmatched and matched cohorts [Hazard Ratio (HR) 1.33 (0.32-5.63), p = 0.695 vs. HR 1.51 (0.28-8.27), p = 0.632, respectively]. Nor were differences found in hospital length of stay, ICU admission and length of stay, or mechanical ventilation requirement and duration between matched and unmatched CS + and CS-. There were no significant differences in the primary and secondary outcomes regarding the use of corticosteroids in patients with viral pneumonia.
Identifiants
pubmed: 39317927
doi: 10.1186/s41479-024-00146-8
pii: 10.1186/s41479-024-00146-8
doi:
Types de publication
Journal Article
Langues
eng
Pagination
21Informations de copyright
© 2024. The Author(s).
Références
Gao CA, Pickens CI, Morales-Nebreda L, Wunderink RG. Clinical features of COVID-19 and differentiation from other causes of CAP. Semin Respir Crit Care Med. 2023;44:8–20.
doi: 10.1055/s-0042-1759889
pubmed: 36646082
WHO Coronavirus (COVID-19). Dashboard. https://covid19.who.int . Accessed 11 Apr 2023.
Torres A, Cilloniz C, Niederman MS, Menéndez R, Chalmers JD, Wunderink RG, et al. Pneumonia Nat Rev Dis Primers. 2021;7:25.
doi: 10.1038/s41572-021-00259-0
pubmed: 33833230
Torres A, Lee N, Cilloniz C, Vila J, Van der Eerden M. Laboratory diagnosis of pneumonia in the molecular age. Eur Respir J. 2016;48:1764–78.
doi: 10.1183/13993003.01144-2016
pubmed: 27811073
Cilloniz C, Luna CM, Hurtado JC, Marcos MÁ, Torres A. Respiratory viruses: their importance and lessons learned from COVID-19. Eur Respir Rev. 2022;31:220051.
doi: 10.1183/16000617.0051-2022
pubmed: 36261158
pmcid: 9724808
Franczuk P, Tkaczyszyn M, Kulak M, Domenico E, Ponikowski P, Jankowska EA. Cardiovascular complications of viral respiratory infections and COVID-19. Biomedicines. 2022;11:71.
doi: 10.3390/biomedicines11010071
pubmed: 36672579
pmcid: 9856218
Caldeira D, Nogueira-Garcia B. Myocardial infarction and viral triggers: what do we know by now? Eur Heart J Suppl. 2023;25(Suppl A):A12–6.
doi: 10.1093/eurheartjsupp/suac122
pubmed: 36937373
pmcid: 10021489
Martin-Loeches I, Torres A. Corticosteroids for CAP, influenza and COVID-19: when, how and benefits or harm? Eur Respir Rev. 2021;30.
Lansbury L, Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Lim WS. Corticosteroids as adjunctive therapy in the treatment of influenza. Cochrane Database Syst Rev. 2019;2:CD010406.
pubmed: 30798570
Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and treatment of adults with community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200:e45–67.
doi: 10.1164/rccm.201908-1581ST
pubmed: 31573350
pmcid: 6812437
ROSENBAUM PR, RUBIN DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41–55.
doi: 10.1093/biomet/70.1.41
Austin PC. An introduction to Propensity score methods for reducing the effects of confounding in Observational studies. Multivar Behav Res. 2011;46:399–424.
doi: 10.1080/00273171.2011.568786
Miké V, Stanley KE. Statistics in medical research: methods and issues, with applications in cancer research. New York: Wiley; 1982.
Cillóniz C, Dominedò C, Magdaleno D, Ferrer M, Gabarrús A, Torres A. Pure viral Sepsis secondary to community-acquired pneumonia in adults: risk and prognostic factors. J Infect Dis. 2019;220:1166–71.
doi: 10.1093/infdis/jiz257
pubmed: 31115456
Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, et al. Community-Acquired Pneumonia requiring hospitalization among U.S. adults. N Engl J Med. 2015;373:415–27.
doi: 10.1056/NEJMoa1500245
pubmed: 26172429
pmcid: 4728150
Torres A, Motos A, Cillóniz C, Ceccato A, Fernández-Barat L, Gabarrús A, et al. Major candidate variables to guide personalised treatment with steroids in critically ill patients with COVID-19: CIBERESUCICOVID study. Intensive Care Med. 2022;48:850–64.
doi: 10.1007/s00134-022-06726-w
pubmed: 35727348
pmcid: 9211796
Delaney JW, Pinto R, Long J, Lamontagne F, Adhikari NK, Kumar A, et al. The influence of corticosteroid treatment on the outcome of influenza A(H1N1pdm09)-related critical illness. Crit Care. 2016;20:75.
doi: 10.1186/s13054-016-1230-8
pubmed: 27036638
pmcid: 4818504
Moreno G, Rodríguez A, Reyes LF, Gomez J, Sole-Violan J, Díaz E, et al. Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching study. Intensive Care Med. 2018;44:1470–82.
doi: 10.1007/s00134-018-5332-4
pubmed: 30074052
pmcid: 7095489
Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam JS, Lim WS. Effect of corticosteroid therapy on influenza-related mortality: a systematic review and meta-analysis. J Infect Dis. 2015;212:183–94.
doi: 10.1093/infdis/jiu645
pubmed: 25406333
Zhang Y, Sun W, Svendsen ER, Tang S, MacIntyre RC, Yang P, et al. Do corticosteroids reduce the mortality of influenza A (H1N1) infection? A meta-analysis. Crit Care. 2015;19:46.
doi: 10.1186/s13054-015-0764-5
pubmed: 25888424
pmcid: 4348153
Yang J-W, Fan L-C, Miao X-Y, Mao B, Li M-H, Lu H-W, et al. Corticosteroids for the treatment of human infection with influenza virus: a systematic review and meta-analysis. Clin Microbiol Infect. 2015;21:956–63.
doi: 10.1016/j.cmi.2015.06.022
pubmed: 26123860
Villar J, Ferrando C, Martínez D, Ambrós A, Muñoz T, Soler JA, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med. 2020;8:267–76.
doi: 10.1016/S2213-2600(19)30417-5
pubmed: 32043986
Annane D, Pastores SM, Rochwerg B, Arlt W, Balk RA, Beishuizen A, et al. Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (part I): society of critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. Crit Care Med. 2017;45:2078–88.
doi: 10.1097/CCM.0000000000002737
pubmed: 28938253
Pirracchio R, Venkatesh B, Legrand M. Low-dose corticosteroids for critically ill adults with severe pulmonary infections: a review. JAMA. 2024;332:318–28.
doi: 10.1001/jama.2024.6096
pubmed: 38865154
See XY, Wang TH, Chang Y-C, Lo J, Liu W, Choo CYW, et al. Impact of different corticosteroids on severe community-acquired pneumonia: a systematic review and meta-analysis. BMJ Open Respir Res. 2024;11:e002141.
doi: 10.1136/bmjresp-2023-002141
pubmed: 38262670
pmcid: 10806634
Wang D, Zhu Y. The complications of corticosteroid for patients with community-acquired Pneumonia: a systematic review and Meta-analysis. Altern Ther Health Med. 2024;:AT10003.